{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:06:18Z","timestamp":1776866778519,"version":"3.51.2"},"reference-count":38,"publisher":"Tohoku University Medical Press","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2023]]},"DOI":"10.1620\/tjem.2022.j109","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T22:10:16Z","timestamp":1671055816000},"page":"199-208","source":"Crossref","is-referenced-by-count":3,"title":["MiR-423-5p Inhibition Exerts Protective Effects on Angiotensin II-Induced Cardiomyocyte Hypertrophy"],"prefix":"10.1620","volume":"259","author":[{"given":"Meng","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Intensive Care Unit, The Affiliated Hospital of Xuzhou Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongchen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Coronary Care Unit, The Affiliated Hospital of Xuzhou Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Burn Orthopedics, The Affiliated Hospital of Xuzhou Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziwen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Unit, The Affiliated Hospital of Xuzhou Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linna","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Unit, The Affiliated Hospital of Xuzhou Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Unit, The Affiliated Hospital of Xuzhou Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"622","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Adebiyi, A.O., Adebiyi, O.O. &amp; Owira, P.M. (2016)  Naringin mitigates cardiac hypertrophy by reducing oxidative stress and inactivating c-Jun Nuclear Kinase-1 protein in type I diabetes.  <i>J. Cardiovasc. Pharmacol<\/i>., 67, 136-144.","DOI":"10.1097\/FJC.0000000000000325"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Bao, Q., Zhao, M., Chen, L., Wang, Y., Wu, S., Wu, W. &amp; Liu, X. (2017)  MicroRNA-297 promotes cardiomyocyte hypertrophy via targeting sigma-1 receptor.  <i>Life Sci<\/i>., 175, 1-10.","DOI":"10.1016\/j.lfs.2017.03.006"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Bartel, D.P. (2004)  MicroRNAs: genomics, biogenesis, mechanism, and function.  <i>Cell<\/i>, 116, 281-297.","DOI":"10.1016\/S0092-8674(04)00045-5"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Bauters, C., Kumarswamy, R., Holzmann, A., Bretthauer, J., Anker, S.D., Pinet, F. &amp; Thum, T. (2013)  Circulating miR-133a and miR-423-5p fail as biomarkers for left ventricular remodeling after myocardial infarction.  <i>Int. J. Cardiol<\/i>., 168, 1837-1840.","DOI":"10.1016\/j.ijcard.2012.12.074"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Bedi, U., Scheel, A.H., Hennion, M., Begus-Nahrmann, Y., Ruschoff, J. &amp; Johnsen, S.A. (2015)  SUPT6H controls estrogen receptor activity and cellular differentiation by multiple epigenomic mechanisms.  <i>Oncogene<\/i>, 34, 465-473.","DOI":"10.1038\/onc.2013.558"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Cai, K. &amp; Chen, H.(2019)  MiR-625-5p inhibits cardiac hypertrophy through targeting STAT3 and CaMKII.  <i>Hum. Gene Ther. Clin. Dev<\/i>., 30, 182-191.","DOI":"10.1089\/humc.2019.087"},{"key":"7","doi-asserted-by":"crossref","unstructured":"D\u2019Alessandra, Y., Chiesa, M., Carena, M.C., Beltrami, A.P., Rizzo, P., Buzzetti, M., Ricci, V., Ferrari, R., Fucili, A., Livi, U., Aleksova, A., Pompilio, G. &amp; Colombo, G.I. (2020)  Differential role of circulating microRNAs to track progression and pre-symptomatic stage of chronic heart failure: a pilot study.  <i>Biomedicines<\/i>, 8, 597.","DOI":"10.3390\/biomedicines8120597"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Dey, S., DeMazumder, D., Sidor, A., Foster, D.B. &amp; O\u2019Rourke, B. (2018)  Mitochondrial ROS drive sudden cardiac death and chronic proteome remodeling in heart failure.  <i>Circ. Res<\/i>., 123, 356-371.","DOI":"10.1161\/CIRCRESAHA.118.312708"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Dickinson, B.A., Semus, H.M., Montgomery, R.L., Stack, C., Latimer, P.A., Lewton, S.M., Lynch, J.M., Hullinger, T.G., Seto, A.G. &amp; van Rooij, E. (2013)  Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure.  <i>Eur. J. Heart Fail<\/i>., 15, 650-659.","DOI":"10.1093\/eurjhf\/hft018"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Duan, J., Hu, H., Zhang, Y., Feng, L., Shi, Y., Miller, M.R. &amp; Sun, Z. (2017)  Multi-organ toxicity induced by fine particulate matter PM(2.5)  in zebrafish (Danio rerio) model.  <i>Chemosphere<\/i>, 180, 24-32.","DOI":"10.1016\/j.chemosphere.2017.04.013"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Goren, Y., Kushnir, M., Zafrir, B., Tabak, S., Lewis, B.S. &amp; Amir, O. (2012)  Serum levels of microRNAs in patients with heart failure.  <i>Eur. J. Heart Fail<\/i>., 14, 147-154.","DOI":"10.1093\/eurjhf\/hfr155"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Huang, Z.P., Chen, J., Seok, H.Y., Zhang, Z., Kataoka, M., Hu, X. &amp; Wang, D.Z. (2013)  MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress.  <i>Circ. Res<\/i>., 112, 1234-1243.","DOI":"10.1161\/CIRCRESAHA.112.300682"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Johar, S., Cave, A.C., Narayanapanicker, A., Grieve, D.J. &amp; Shah, A.M. (2006)  Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase.  <i>FASEB J<\/i>., 20, 1546-1548.","DOI":"10.1096\/fj.05-4642fje"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Keith, M., Geranmayegan, A., Sole, M.J., Kurian, R., Robinson, A., Omran, A.S. &amp; Jeejeebhoy, K.N. (1998)  Increased oxidative stress in patients with congestive heart failure.  <i>J. Am. Coll. Cardiol<\/i>., 31, 1352-1356.","DOI":"10.1016\/S0735-1097(98)00101-6"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Lee, J.S., Yang, D.K., Park, J.H., Kim, J.O., Park, W.J., Cho, C. &amp; Kim, D.H. (2017)  MicroRNA-101b attenuates cardiomyocyte hypertrophy by inhibiting protein kinase C epsilon signaling.  <i>FEBS Lett<\/i>., 591, 16-27.","DOI":"10.1002\/1873-3468.12508"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Li, K., Lin, Y. &amp; Li, C. (2019)  MiR-338-5p ameliorates pathological cardiac hypertrophy by targeting CAMKII<i>\u03b4<\/i>.  <i>Arch. Pharm. Res<\/i>., 42, 1071-1080.","DOI":"10.1007\/s12272-019-01199-w"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Lyu, L., Wang, H., Li, B., Qin, Q., Qi, L., Nagarkatti, M., Nagarkatti, P., Janicki, J.S., Wang, X.L. &amp; Cui, T. (2015)  A critical role of cardiac fibroblast-derived exosomes in activating renin angiotensin system in cardiomyocytes.  <i>J. Mol. Cell. Cardiol<\/i>., 89, 268-279.","DOI":"10.1016\/j.yjmcc.2015.10.022"},{"key":"18","unstructured":"Nabialek, E., Wanha, W., Kula, D., Jadczyk, T., Krajewska, M., Kowalowka, A., Dworowy, S., Hrycek, E., Wludarczyk, W., Parma, Z., Michalewska-Wludarczyk, A., Pawlowski, T., Ochala, B., Jarzab, B., Tendera, M.,  et al. (2013)  Circulating microRNAs (miR-423-5p, miR-208a and miR-1) in acute myocardial infarction and stable coronary heart disease.  <i>Minerva Cardioangiol<\/i>., 61, 627-637."},{"key":"19","doi-asserted-by":"crossref","unstructured":"Nakamura, M. &amp; Sadoshima, J. (2018)  Mechanisms of physiological and pathological cardiac hypertrophy.  <i>Nat. Rev. Cardiol<\/i>., 15, 387-407.","DOI":"10.1038\/s41569-018-0007-y"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Nie, X., Fan, J., Li, H., Yin, Z., Zhao, Y., Dai, B., Dong, N., Chen, C. &amp; Wang, D.W. (2018)  miR-217 promotes cardiac hypertrophy and dysfunction by targeting PTEN.  <i>Mol. Ther. Nucleic Acids<\/i>, 12, 254-266.","DOI":"10.1016\/j.omtn.2018.05.013"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Oliveira-Carvalho, V., Carvalho, V.O., Silva, M.M., Guimaraes, G.V. &amp; Bocchi, E.A. (2012)  MicroRNAs: a new paradigm in the treatment and diagnosis of heart failure?  <i>Arq. Bras. Cardiol.<\/i>, 98, 362-369.","DOI":"10.1590\/S0066-782X2012000400011"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Oliveira-Carvalho, V., da Silva, M.M., Guimaraes, G.V., Bacal, F. &amp; Bocchi, E.A. (2013)  MicroRNAs: new players in heart failure.  <i>Mol. Biol. Rep<\/i>., 40, 2663-2670.","DOI":"10.1007\/s11033-012-2352-y"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Orenes-Pi\u00f1ero, E., Montoro-Garcia, S., Patel, J.V., Valdes, M., Marin, F. &amp; Lip, G.Y. (2013)  Role of microRNAs in cardiac remodelling: new insights and future perspectives.  <i>Int. J. Cardiol<\/i>., 167, 1651-1659.","DOI":"10.1016\/j.ijcard.2012.09.120"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Peterlin, A., Pocivavsek, K., Petrovic, D. &amp; Peterlin, B. (2020)  The role of microRNAs in heart failure: a systematic review.  <i>Front. Cardiovasc. Med<\/i>., 7, 161.","DOI":"10.3389\/fcvm.2020.00161"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Rababa\u2019h, A.M., Guillory, A.N., Mustafa, R. &amp; Hijjawi, T. (2018)  Oxidative stress and cardiac remodeling: an updated edge.  <i>Curr. Cardiol. Rev<\/i>., 14, 53-59.","DOI":"10.2174\/1573403X14666180111145207"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Rizzacasa, B., Morini, E., Mango, R., Vancheri, C., Budassi, S., Massaro, G., Maletta, S., Macrini, M., D\u2019Annibale, S., Romeo, F., Novelli, G. &amp; Amati, F. (2019)  MiR-423 is differentially expressed in patients with stable and unstable coronary artery disease: a pilot study.  <i>PLoS One<\/i>, 14, e0216363.","DOI":"10.1371\/journal.pone.0216363"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Rosca, M.G., Tandler, B. &amp; Hoppel, C.L. (2013)  Mitochondria in cardiac hypertrophy and heart failure.  <i>J. Mol. Cell. Cardiol<\/i>., 55, 31-41.","DOI":"10.1016\/j.yjmcc.2012.09.002"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Seddon, M., Looi, Y.H. &amp; Shah, A.M. (2007)  Oxidative stress and redox signalling in cardiac hypertrophy and heart failure.  <i>Heart<\/i>, 93, 903-907.","DOI":"10.1136\/hrt.2005.068270"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Seok, H., Lee, H., Lee, S., Ahn, S.H., Lee, H.S., Kim, G.D., Peak, J., Park, J., Cho, Y.K., Jeong, Y., Gu, D., Jeong, Y., Eom, S., Jang, E.S. &amp; Chi, S.W. (2020)  Position-specific oxidation of miR-1 encodes cardiac hypertrophy.  <i>Nature<\/i>, 584, 279-285.","DOI":"10.1038\/s41586-020-2586-0"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Shah, R., Ziegler, O., Yeri, A., Liu, X., Murthy, V., Rabideau, D., Xiao, C.Y., Hanspers, K., Belcher, A., Tackett, M., Rosenzweig, A., Pico, A.R., Januzzi, J.L. &amp; Das, S. (2018)  MicroRNAs associated with reverse left ventricular remodeling in humans identify pathways of heart failure progression.  <i>Circ. Heart Fail<\/i>., 11, e004278.","DOI":"10.1161\/CIRCHEARTFAILURE.117.004278"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Sun, B., Huo, R., Sheng, Y., Li, Y., Xie, X., Chen, C., Liu, H.B., Li, N., Li, C.B., Guo, W.T., Zhu, J.X., Yang, B.F. &amp; Dong, D.L. (2013)  Bone morphogenetic protein-4 mediates cardiac hypertrophy, apoptosis, and fibrosis in experimentally pathological cardiac hypertrophy.  <i>Hypertension<\/i>, 61, 352-360.","DOI":"10.1161\/HYPERTENSIONAHA.111.00562"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Tang, L., Xie, J., Yu, X. &amp; Zheng, Y. (2020)  MiR-26a-5p inhibits GSK3beta expression and promotes cardiac hypertrophy in vitro.  <i>PeerJ<\/i>, 8, e10371.","DOI":"10.7717\/peerj.10371"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Thompson, B.S. (2009)  Sudden cardiac death and heart failure.  <i>AACN Adv. Crit. Care<\/i>, 20, 356-365.","DOI":"10.1097\/NCI.0b013e3181b82379"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Tijsen, A.J., Creemers, E.E., Moerland, P.D., de Windt, L.J., van der Wal, A.C., Kok, W.E. &amp; Pinto, Y.M. (2010)  MiR423-5p as a circulating biomarker for heart failure.  <i>Circ. Res<\/i>., 106, 1035-1039.","DOI":"10.1161\/CIRCRESAHA.110.218297"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Tutarel, O., Dangwal, S., Bretthauer, J., Westhoff-Bleck, M., Roentgen, P., Anker, S.D., Bauersachs, J. &amp; Thum, T. (2013)  Circulating miR-423_5p fails as a biomarker for systemic ventricular function in adults after atrial repair for transposition of the great arteries.  <i>Int. J. Cardiol<\/i>., 167, 63-66.","DOI":"10.1016\/j.ijcard.2011.11.082"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Yan, P., Wang, Y., Meng, X., Yang, H., Liu, Z., Qian, J., Zhou, W. &amp; Li, J. (2019)  Whole exome sequencing of ulcerative colitis-associated colorectal cancer based on novel somatic mutations identified in Chinese patients.  <i>Inflamm. Bowel Dis<\/i>., 25, 1293-1301.","DOI":"10.1093\/ibd\/izz020"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Zhang, S., Yin, Z., Dai, F.F., Wang, H., Zhou, M.J., Yang, M.H., Zhang, S.F., Fu, Z.F., Mei, Y.W., Zang, M.X. &amp; Xue, L. (2019)  miR-29a attenuates cardiac hypertrophy through inhibition of PPAR<i>\u03b4<\/i> expression.  <i>J. Cell. Physiol<\/i>., 234, 13252-13262.","DOI":"10.1002\/jcp.27997"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Zhu, X. &amp; Lu, X. (2019)  MiR-423-5p inhibition alleviates cardiomyocyte apoptosis and mitochondrial dysfunction caused by hypoxia\/reoxygenation through activation of the wnt\/beta-catenin signaling pathway via targeting MYBL2.  <i>J. Cell. Physiol<\/i>., 234, 22034-22043.","DOI":"10.1002\/jcp.28766"}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/259\/3\/259_2022.J109\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T05:46:20Z","timestamp":1676699180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/259\/3\/259_2022.J109\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.2022.j109","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"2022.J109"}}